DK2001892T3 - Imidazolthiazolforbindelser til behandling af proliferative sygdomme - Google Patents

Imidazolthiazolforbindelser til behandling af proliferative sygdomme

Info

Publication number: DK2001892T3
Authority: DK; Denmark
Prior art keywords: imidazolthiazol; compounds; proliferative diseases; treating proliferative; treating
Prior art date: 2006-03-17

Application number

DK07753256T

Other languages

English (en)

Inventor

Shripad Bhagwat

Qi Chao

Hitesh K Patel

Kelly G Sprankle

Robert M Grotzfeld

Original Assignee

Ambit Biosciences Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-03-17

Filing date

2007-03-16

Publication date

2013-07-01

2007-03-16 Application filed by Ambit Biosciences Corp filed Critical Ambit Biosciences Corp

2013-07-01 Application granted granted Critical

2013-07-01 Publication of DK2001892T3 publication Critical patent/DK2001892T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

DK07753256T 2006-03-17 2007-03-16 Imidazolthiazolforbindelser til behandling af proliferative sygdomme DK2001892T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US74354306P	2006-03-17	2006-03-17
PCT/US2007/006613 WO2007109120A2 (en)	2006-03-17	2007-03-16	Imidazolothiazole compounds for the treatment of disease

Publications (1)

Publication Number	Publication Date
DK2001892T3 true DK2001892T3 (da)	2013-07-01

Family

ID=38522967

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK07753256T DK2001892T3 (da)	2006-03-17	2007-03-16	Imidazolthiazolforbindelser til behandling af proliferative sygdomme

Country Status (23)

Country	Link
US (6)	US7820657B2 (da)
EP (1)	EP2001892B1 (da)
JP (2)	JP4610668B2 (da)
KR (2)	KR101549364B1 (da)
CN (1)	CN101448843B (da)
AU (1)	AU2007227495B2 (da)
BR (1)	BRPI0708823B1 (da)
CA (1)	CA2646437C (da)
DK (1)	DK2001892T3 (da)
ES (1)	ES2422890T3 (da)
HK (1)	HK1131141A1 (da)
IL (1)	IL194076A (da)
MX (1)	MX2008011684A (da)
MY (1)	MY145070A (da)
NO (1)	NO342985B1 (da)
NZ (1)	NZ571566A (da)
PL (1)	PL2001892T3 (da)
PT (1)	PT2001892E (da)
RU (1)	RU2441011C2 (da)
SI (1)	SI2001892T1 (da)
TW (1)	TWI409267B (da)
WO (1)	WO2007109120A2 (da)
ZA (1)	ZA200808178B (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101549364B1 (ko) *	2006-03-17	2015-09-01	암비트 바이오사이언시즈 코포레이션	질환 치료용 이미다졸로티아졸 화합물
US8883783B2 (en) *	2007-09-19	2014-11-11	Ambit Biosciences Corporation	Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith
CA2696807C (en)	2007-11-08	2017-11-28	Ambit Biosciences Corp.	Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
US7825214B2 (en) *	2008-01-15	2010-11-02	Johns Manville	Purified styrene-maleic anhydride polymer binder
WO2010054058A1 (en) *	2008-11-06	2010-05-14	Ambit Bioscience Corporation	Imidazolothiazole compounds as modulators of protein kinase
EP2218464A1 (en) *	2009-02-11	2010-08-18	Technische Universität München	Compounds for non-invasive measurement of aggregates of amyloid peptides
RU2543348C2 (ru) *	2009-03-23	2015-02-27	Эмбит Байосайенсиз Корпорейшн	Способ лечения путем применения комбинированной терапии
SMT202000092T1 (it) *	2009-05-14	2020-05-08	Ambit Biosciences Corp	Formulazione essiccata a spruzzo o liofilizzata di ac220
EP2305688A1 (en) *	2009-09-28	2011-04-06	Université de la Méditerranée - Aix-Marseille II	Novel aminoacids derivatives, their process of preparation and their therapeutical uses as MET inhibitors
WO2011056764A1 (en) *	2009-11-05	2011-05-12	Ambit Biosciences Corp.	Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
CA2778940C (en) *	2009-11-05	2018-10-16	Ambit Biosciences Corp.	Process for the preparation of imidazo[2,1-b][1,3]benzothiazole derivatives
HUE045270T2 (hu)	2010-01-05	2019-12-30	Inst Nat Sante Rech Med	FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
CN110003209B (zh)	2010-05-20	2022-01-25	阵列生物制药公司	作为trk激酶抑制剂的大环化合物
DE102011113749A1 (de) *	2011-09-14	2013-03-14	Aicuris Gmbh & Co. Kg	Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole
EP2766359B9 (en) *	2011-10-14	2017-04-05	Ambit Biosciences Corporation	Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
CN103172648B (zh) *	2011-12-20	2016-05-25	上海迪诺医药科技有限公司	三杂环衍生物、制备方法及应用
CA2870264C (en)	2012-04-17	2016-11-08	Fujifilm Corporation	Nitrogen-containing heterocyclic compound or salt thereof
JP6116847B2 (ja)	2012-10-01	2017-04-19	アムビトバイオサイエンシスコーポレーションＡｍｂｉｔＢｉｏｓｃｉｅｎｃｅｓＣｏｒｐｏｒａｔｉｏｎ	シクロデキストリンとの混合体を含有する錠剤
WO2015043492A1 (en) *	2013-09-26	2015-04-02	Sunshine Lake Pharma Co., Ltd.	Substituted urea derivatives and uses thereof in medicine
CN104513258B (zh) *	2013-09-26	2018-04-03	广东东阳光药业有限公司	取代脲衍生物及其在药物中的应用
AU2014335312B9 (en)	2013-10-16	2017-05-25	Fujifilm Corporation	Salt of nitrogen-containing heterocyclic compound or crystal thereof, pharmaceutical composition, and FLT3 inhibitor
GB201321730D0 (en) *	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic agents
GB201321728D0 (en) *	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic agents
SG11201608303QA (en)	2014-04-04	2016-11-29	Del Mar Pharmaceuticals	Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
HUE046008T2 (hu) *	2014-07-17	2020-02-28	Sunshine Lake Pharma Co Ltd	I-(5-terc-butil)-izoxazol-3-il)-3-(4-((feniI)-etinil)-fenil)-kabamid származékok, valamint az ezekkel rokon vegyületek FLT-3 inhibitorokként rák kezelésére
AU2015295288B2 (en)	2014-07-31	2019-10-31	Centre National De La Recherche Scientifique (Cnrs)	FLT3 receptor antagonists
BR112017003186A2 (pt)	2014-08-22	2017-11-28	Fujifilm Corp	composição farmacêutica para tratamento de cancer positivo para mutação em flt3, inibidor de flt3 mutante e usos dos mesmos
CR20170094A (es) *	2014-09-10	2017-05-08	Glaxosmithkline Ip Dev Ltd	Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret)
CN105461709B (zh) *	2014-09-26	2020-01-21	广东东阳光药业有限公司	取代脲衍生物及其在药物中的应用
CN105801602B (zh) *	2014-12-31	2018-05-04	四川大学	5-叔丁基异噁唑-3-基-3-(4-取代苯基)脲衍生物及其制备方法和用途
JP6564449B2 (ja)	2015-02-20	2019-08-21	第一三共株式会社	がんの併用治療法
JP6412471B2 (ja)	2015-07-15	2018-10-24	富士フイルム株式会社	含窒素複素環化合物の製造方法およびその中間体
US10023570B2 (en)	2015-07-16	2018-07-17	Array Biopharma Inc.	Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
WO2017157813A1 (en)	2016-03-15	2017-09-21	F. Hoffmann-La Roche Ag	Combinations of lsd1 inhibitors for the treatment of hematological malignancies
EP3254698A1 (en)	2016-06-08	2017-12-13	Universite De Montpellier	Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
TWI704148B (zh)	2016-10-10	2020-09-11	美商亞雷生物製藥股份有限公司	作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar)	2016-10-10	2019-04-09	Array Biopharma Inc	مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
CN110267960B (zh)	2017-01-18	2022-04-26	阿雷生物药品公司	作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
WO2018136663A1 (en)	2017-01-18	2018-07-26	Array Biopharma, Inc.	Ret inhibitors
JOP20190213A1 (ar)	2017-03-16	2019-09-16	Array Biopharma Inc	مركبات حلقية ضخمة كمثبطات لكيناز ros1
WO2018211018A1 (en)	2017-05-17	2018-11-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Flt3 inhibitors for improving pain treatments by opioids
TWI791053B (zh)	2017-10-10	2023-02-01	美商亞雷生物製藥股份有限公司	6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh)	2017-10-10	2023-08-21	美商絡速藥業公司	6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI802635B (zh)	2018-01-18	2023-05-21	美商亞雷生物製藥股份有限公司	作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物
US11524963B2 (en)	2018-01-18	2022-12-13	Array Biopharma Inc.	Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
CN111615514B (zh)	2018-01-18	2022-10-11	奥瑞生物药品公司	作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
CA3111984A1 (en)	2018-09-10	2020-03-19	Array Biopharma Inc.	Fused heterocyclic compounds as ret kinase inhibitors
IT201900015030A1 (it) *	2019-08-26	2021-02-26	Univ Degli Studi Di Palermo	Nuovi agenti terapeutici per il trattamento di patologie ematologiche
CN113966331B (zh) *	2020-03-11	2024-04-12	暨南大学	含脲结构的三芳环化合物及其应用
CN111362972B (zh) *	2020-04-28	2021-08-24	江南大学	一种苯并咪唑并[2,1-b]噻唑类化合物及其应用
IL279972A (en) *	2021-01-05	2022-08-01	Anima Biotech Inc	C-myc mrna translation modulators and uses thereof in the treatment of cancer
WO2024010761A1 (en) *	2022-07-03	2024-01-11	Anima Biotech Inc.	C-myc mrna translation modulators and uses thereof in the treatment of cancer
CN115650978A (zh) *	2022-10-16	2023-01-31	河南师范大学	一种7-烷氧基二氢咪唑并[4,5-b]哌啶-2-硫酮类化合物的合成方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL129432C (da) *	1964-02-29
NL129626C (da) *	1964-04-08
US3210370A (en) *	1964-06-22	1965-10-05	Upjohn Co	Process for preparing 2, 2'-methylene-bisareneimiazoles
FR2463774A1 (fr) *	1979-08-21	1981-02-27	Yamanouchi Pharma Co Ltd	Derives du 2-phenylimidazo(2,1-b)benzothiazole
US4354970A (en) *	1980-03-07	1982-10-19	Eastman Kodak Company	Indoline coupled isothiazole azo dyes
JPS56138196A (en)	1980-03-29	1981-10-28	Yamanouchi Pharmaceut Co Ltd	Imidazo (2,1-b)benzothiazole derivative
JPS5740492A (en)	1980-08-22	1982-03-06	Yamanouchi Pharmaceut Co Ltd	Novel 2-phenylimidazo 2,1-b benzothiazole derivative
JPS57149288A (en)	1981-03-12	1982-09-14	Yamanouchi Pharmaceut Co Ltd	Imidazo(2,1-b)benzothiazole derivative
EP0082715A3 (en) *	1981-12-21	1984-01-11	Viragate Limited	A target apparatus
US4464384A (en) *	1981-12-23	1984-08-07	Yamanouchi Pharmaceutical Co., Ltd.	2-Phenylimidazo[2,1-b]benzothiazole compounds, salts thereof, process of producing them, and pharmaceutical compositions containing them
JPS5978194A (ja) *	1982-10-27	1984-05-04	Yamanouchi Pharmaceut Co Ltd	２−フエニルイミダゾ〔２，１−ｂ〕ベンゾチアゾ−ルの新規誘導体およびその製造法
US5236952A (en) *	1986-03-11	1993-08-17	Hoffmann-La Roche Inc.	Catechol derivatives
US4880824A (en) *	1987-09-21	1989-11-14	Ortho Pharmaceutical Corporation	Phenyl and benzoyl substituted imidazo-fused heterocyclic calcium channel blockers
EP0524055A1 (fr)	1991-07-19	1993-01-20	Synthelabo	Dérivés d'imidazo[2,1-b]benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique
JPH05107705A (ja)	1991-10-17	1993-04-30	Konica Corp	新規な写真用カプラー
ES2126636T3 (es) *	1992-05-19	1999-04-01	Adir	Derivados del bencimidazol con actividad antidiabetica y antiagregante plaquetaria.
FR2699920B1 (fr)	1992-12-24	1995-02-10	Synthelabo	Dérivés d'imidazo [2,1-b] benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique.
FR2700546B1 (fr)	1993-01-15	1995-02-17	Synthelabo	Dérivés d'imidazo[2,1-b]benzoxazole-3-acétamide, leur préparation et leur application en thérapeutique.
EP0607076A1 (fr) *	1993-01-15	1994-07-20	Synthelabo	Dérivés de 9h-imidazo 1,2-a benzimidazole-3-acétamide à activité GABA
JPH07291976A (ja)	1994-04-27	1995-11-07	Otsuka Pharmaceut Factory Inc	イミダゾ〔２，１−ｂ〕チアゾール誘導体
FR2722501B1 (fr)	1994-07-13	1996-08-09	Synthelabo	Derives de 9h-imidazo(1,2-a)benzimidazole-3-acetamide, leur preparation et leur application en therapeutique
US5466799A (en) *	1994-08-08	1995-11-14	Iowa State University Research Foundation, Inc.	Synthesis of benzodiazepines
WO1996028454A1 (fr) *	1995-03-13	1996-09-19	Nikken Chemicals Co., Ltd.	Composes imidazothiazole
AU3783497A (en)	1996-08-09	1998-03-06	Yamanouchi Pharmaceutical Co., Ltd.	Metabotropic glutamate receptor agonists
FR2759698B1 (fr)	1997-02-20	1999-03-19	Synthelabo	Derives de 1,4-diphenylimidazole-5-acetamide, leur preparation et leur application en therapeutique
JPH11106340A (ja) *	1997-10-02	1999-04-20	Sumitomo Pharmaceut Co Ltd	Ｓｔａｔ６活性化阻害剤
CZ299156B6 (cs)	1997-12-22	2008-05-07	Bayer Corporation	Substituované heterocyklické mocoviny, farmaceutické prípravky je obsahující a jejich použití
DE19805117A1 (de)	1998-02-09	1999-08-12	Bayer Ag	Neue Oxazolidinone mit azolhaltigen Tricyclen
DE19905278A1 (de)	1999-02-09	2000-08-10	Bayer Ag	Oxazolidinone und ihre Verwendung als antibakterielle Mittel
GB2351081A (en)	1999-06-18	2000-12-20	Lilly Forschung Gmbh	Pharmaceutically active imidazoline compounds and analogues thereof
JP2001048786A (ja) *	1999-08-05	2001-02-20	Yamanouchi Pharmaceut Co Ltd	三環式ヘテロアリール誘導体
DE19948434A1 (de)	1999-10-08	2001-06-07	Gruenenthal Gmbh	Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
JP2001192386A (ja)	1999-10-29	2001-07-17	Meiji Seika Kaisha Ltd	新規トリアゾール誘導体及びこれを有効成分とする抗真菌剤
DE10019714A1 (de) *	2000-04-20	2002-01-10	Gruenenthal Gmbh	Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen
WO2002004409A2 (en)	2000-07-06	2002-01-17	Us Gov Health & Human Serv	Tetrahydrobenzothiazole analogues as neuroprotective agents
US6696441B1 (en)	2000-08-11	2004-02-24	The Regents Of The University Of California	Inhibition of p53-induced stress response
US7601846B2 (en) *	2001-06-26	2009-10-13	The Regents Of The University Of California	Compounds having activity as inhibitors of apoptosis
US20030143199A1 (en)	2001-10-09	2003-07-31	Carson Dennis A.	Use of STAT-6 inhibitors as therapeutic agents
US20040127719A1 (en) *	2002-03-08	2004-07-01	Kexin Yang	Alpha-isocyanocarboxylate solid support templates, method of preparation and for using the same
EP1565459A2 (en)	2002-11-25	2005-08-24	Pharmacia Corporation	Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors
WO2004058758A1 (en)	2002-12-18	2004-07-15	Mallinckrodt Inc.	Synthesis of heteroaryl acetamides
KR100647583B1 (ko) *	2003-10-07	2006-11-17	삼성에스디아이 주식회사	이미다졸 고리 함유 화합물 및 이를 이용한 유기 전계발광 소자
US20050165031A1 (en) *	2003-11-13	2005-07-28	Ambit Biosciences Corporation	Urea derivatives as ABL modulators
KR101549364B1 (ko) *	2006-03-17	2015-09-01	암비트 바이오사이언시즈 코포레이션	질환 치료용 이미다졸로티아졸 화합물
US8883783B2 (en) *	2007-09-19	2014-11-11	Ambit Biosciences Corporation	Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith
CA2696807C (en) *	2007-11-08	2017-11-28	Ambit Biosciences Corp.	Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
WO2010054058A1 (en) *	2008-11-06	2010-05-14	Ambit Bioscience Corporation	Imidazolothiazole compounds as modulators of protein kinase
RU2543348C2 (ru) *	2009-03-23	2015-02-27	Эмбит Байосайенсиз Корпорейшн	Способ лечения путем применения комбинированной терапии
SMT202000092T1 (it) *	2009-05-14	2020-05-08	Ambit Biosciences Corp	Formulazione essiccata a spruzzo o liofilizzata di ac220

2007
- 2007-03-16 KR KR1020147018402A patent/KR101549364B1/ko active IP Right Grant
- 2007-03-16 CA CA2646437A patent/CA2646437C/en active Active
- 2007-03-16 PT PT77532562T patent/PT2001892E/pt unknown
- 2007-03-16 AU AU2007227495A patent/AU2007227495B2/en active Active
- 2007-03-16 DK DK07753256T patent/DK2001892T3/da active
- 2007-03-16 EP EP20070753256 patent/EP2001892B1/en active Active
- 2007-03-16 ES ES07753256T patent/ES2422890T3/es active Active
- 2007-03-16 TW TW96109141A patent/TWI409267B/zh active
- 2007-03-16 WO PCT/US2007/006613 patent/WO2007109120A2/en active Application Filing
- 2007-03-16 KR KR1020087025308A patent/KR101449057B1/ko active IP Right Grant
- 2007-03-16 JP JP2009500500A patent/JP4610668B2/ja active Active
- 2007-03-16 US US11/724,992 patent/US7820657B2/en active Active
- 2007-03-16 SI SI200731239T patent/SI2001892T1/sl unknown
- 2007-03-16 PL PL07753256T patent/PL2001892T3/pl unknown
- 2007-03-16 MY MYPI20083616 patent/MY145070A/en unknown
- 2007-03-16 RU RU2008141169A patent/RU2441011C2/ru active
- 2007-03-16 NZ NZ571566A patent/NZ571566A/en unknown
- 2007-03-16 MX MX2008011684A patent/MX2008011684A/es active IP Right Grant
- 2007-03-16 CN CN2007800177601A patent/CN101448843B/zh active Active
- 2007-03-16 BR BRPI0708823-0A patent/BRPI0708823B1/pt active IP Right Grant
2008
- 2008-09-14 IL IL194076A patent/IL194076A/en active IP Right Grant
- 2008-09-25 ZA ZA2008/08178A patent/ZA200808178B/en unknown
- 2008-10-17 NO NO20084374A patent/NO342985B1/no unknown
2009
- 2009-11-19 HK HK09110846A patent/HK1131141A1/xx unknown
2010
- 2010-08-04 US US12/850,557 patent/US8129374B2/en active Active
- 2010-08-31 JP JP2010194909A patent/JP5395017B2/ja active Active
2012
- 2012-01-24 US US13/357,477 patent/US8557810B2/en active Active
2013
- 2013-09-20 US US14/033,299 patent/US8921546B2/en active Active
2014
- 2014-10-31 US US14/530,383 patent/US20150126505A1/en not_active Abandoned
2017
- 2017-06-26 US US15/633,620 patent/US20170348320A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MX2008011684A (es)	2008-12-12
EP2001892B1 (en)	2013-04-24
US20140243525A1 (en)	2014-08-28
CA2646437C (en)	2016-05-17
CN101448843B (zh)	2012-05-09
RU2008141169A (ru)	2010-04-27
ES2422890T3 (es)	2013-09-16
JP5395017B2 (ja)	2014-01-22
WO2007109120A3 (en)	2007-12-27
NZ571566A (en)	2011-07-29
SI2001892T1 (sl)	2013-07-31
KR20140091619A (ko)	2014-07-21
US8129374B2 (en)	2012-03-06
US20150126505A1 (en)	2015-05-07
JP2011037858A (ja)	2011-02-24
US8921546B2 (en)	2014-12-30
JP2009530300A (ja)	2009-08-27
TW200801021A (en)	2008-01-01
PL2001892T3 (pl)	2013-09-30
AU2007227495A1 (en)	2007-09-27
BRPI0708823A2 (pt)	2011-06-14
KR101549364B1 (ko)	2015-09-01
NO20084374L (no)	2008-11-05
IL194076A (en)	2015-05-31
JP4610668B2 (ja)	2011-01-12
TWI409267B (zh)	2013-09-21
CA2646437A1 (en)	2007-09-27
US8557810B2 (en)	2013-10-15
CN101448843A (zh)	2009-06-03
IL194076A0 (en)	2009-09-22
HK1131141A1 (en)	2010-01-15
US20170348320A1 (en)	2017-12-07
WO2007109120A2 (en)	2007-09-27
US20070232604A1 (en)	2007-10-04
US20100298313A1 (en)	2010-11-25
EP2001892A2 (en)	2008-12-17
KR20080108548A (ko)	2008-12-15
ZA200808178B (en)	2010-11-24
NO342985B1 (no)	2018-09-17
US7820657B2 (en)	2010-10-26
KR101449057B1 (ko)	2014-10-10
BRPI0708823B1 (pt)	2022-01-18
PT2001892E (pt)	2013-07-04
US20120129850A1 (en)	2012-05-24
AU2007227495B2 (en)	2013-02-21
MY145070A (en)	2011-12-15
RU2441011C2 (ru)	2012-01-27

Publication	Publication Date	Title
DK2001892T3 (da)	2013-07-01	Imidazolthiazolforbindelser til behandling af proliferative sygdomme
LTPA2020501I1 (lt)	2020-02-10	Pakeistieji enaminokarbonilo junginiai
DK3289876T3 (da)	2022-10-10	Forbindelser til behandling af cancer
DK2046767T3 (da)	2015-06-22	Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
BRPI0716435A2 (pt)	2014-03-04	Compostos para o tratamento de doenças proliferativas
DK2086944T3 (da)	2010-05-03	Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK2478907T3 (da)	2021-05-25	Sammensætninger til behandling af kræft
DK2310034T3 (da)	2014-04-28	Peptider til behandling af beta-amyloidose
IL197217B (en)	2019-12-31	Novel anti-cd38 antibodies for the treatment of cancer
DK1874781T3 (da)	2009-11-02	Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK2081595T3 (da)	2019-07-15	Anti-cd38 plus corticosteroid plus et ikke-corticosteroid kemoterapeutikum til behandling af tumorer
BRPI0815042A2 (pt)	2015-02-10	Compostos de pirazol
DK2209743T3 (da)	2019-10-07	Aggregatsammensætning til behandling af en kontamineret væske
DK2440545T3 (da)	2019-07-22	Forbindelser, der er anvendelige til behandling af cancer
ATE524477T1 (de)	2011-09-15	Aziridinylepothilonverbindungen
BRPI0716844A2 (pt)	2013-10-22	Inidores de quinase úteis para o tratamento de doenças proliferativas
BRPI0815067A2 (pt)	2015-02-10	Compostos de biciclotactama substituída
DK2865422T3 (da)	2017-11-20	Alpha-msh-derivater til behandling af fotodermatoser
DK2215031T3 (da)	2019-05-06	Fremgangsmåde til bearbejdning af pozzolaner
DK2209784T3 (da)	2012-10-29	Forbindelser til behandling af hepatitis C
DK2061746T3 (da)	2013-11-25	Fremgangsmåde til fremstilling af diestere
DK2213654T3 (da)	2014-04-22	Fremgangsmåde til fremstilling af 2-amino-5-brombenzamid derivater
BRPI0809996A2 (pt)	2014-10-14	Compostos
DK2452189T3 (da)	2014-01-20	Fremgangsmåde til identifikation af forbindelser til behandling af cancer
DK2117565T3 (da)	2012-11-19	Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme